Abstract
Many of the recent advancements in the area of tumor immunobiology have allowed us to focus our efforts on the experimental treatment of patients with metastatic melanoma. It has been both a frustrating and often a seemingly futile effort on the parts of physicians and researchers alike in treating such patients. The last decade of research has resulted in a paradigm shift in our understanding of the immunologic interactions between a tumor cell and the host immune response. The discovery and clinical application of tumor-associated antigens has allowed for a selective and highly specific approach to the treatment of patients with stage IV metastatic melanoma (1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D., et al. (1998) Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321–327.
Riker, A. I., Panelli, M. C., Kammula, U. S., et al. (1999) Development and characterization of melanoma cell lines established by fine needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. Cancer Detection Prevention 23(5), 387–396.
Brodsky, F. M. and Parham, P. (1982) Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. J. Immunol. 128, 129–135.
Tsujisaki, M., Sakaguchi, K., Igarashi, M., et al. (1988) Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation 45, 632–639.
Marincola, F. M., Hijazi, Y. M., Fetsch, P., et al. (1996) Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother. 19, 192–205.
Kawakami, Y., Battles, J. K., Kobayashi, T., et al. (1997) Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J. Immunol. Methods 202, 13–25.
Cormier, J. N., Panelli, M. C., Hackett, J. A., et al. (1999) Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int. J. Cancer 80, 271–280.
Bunce, M., O’Neill, C. M., Barnardo, M. C., et al. (1995) Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46, 355–367.
Player, M. A., Barracchini, K. C., Simonis, T. B., et al. (1996) Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J. Immunother. 19, 357–363.
Zajdela, A., Ennuyer, A., Bataini, P., et al. (1976) Value of the cytologic diagnosis of adenopathies by aspiration biopsy: cytohistologic comparison of 1756 cases. Bull. Cancer 63, 327–340.
Engzell, U., Jakobsson, P. A., Sigurdson, A., et al. (1971) Aspiration biopsy of metastatic carcinoma in lymph nodes of the neck: a review of 1101 consecutive cases. Acta Otolaryngol. (Stockh.) 72, 138–147.
Li, Z., Bustos, V., Miner, J., et al. (1998) Propagation of genetically altered tumor cells derived from fine-needle aspirates of primary breast carcinoma. Cancer Res. 58, 5271–5274.
Scheibenbogen, C., Weyers, I., Ruiter, D. J., et al. (1996) Expression of gp100 in melanoma metastases resected before and after treatment with IFN and IL-2. J. Immunother. 19, 375–380.
de Vries, T. J., Fourkour, A., Wobbes, T., et al. (1997) Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57, 3223–3229.
Lehmann, F., Marchand, M., Hainaut, P., et al. (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25 340–347.
Riker, A. I., Kammula, U. S., Panelli, M. C., et al. (1999) Immune selection following antigen specific immunotherapy of melanoma. Surgery 126, 112–118.
Jager, E., Ringhoffer, M., Karbach, M., et al. (1996) Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66, 470–476.
Jager, E., Ringhoffer, M., Altmannsberger, M., et al. (1997) Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71, 142–147.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Riker, A.I. (2001). Utility of Fine-Needle Aspiration Biopsy for Prospective Analysis of Patients Undergoing Therapy for Metastatic Melanoma. In: Nickoloff, B.J., Hood, L. (eds) Melanoma Techniques and Protocols. Methods in Molecular Medicine, vol 61. Humana Press. https://doi.org/10.1385/1-59259-145-0:287
Download citation
DOI: https://doi.org/10.1385/1-59259-145-0:287
Publisher Name: Humana Press
Print ISBN: 978-0-89603-684-0
Online ISBN: 978-1-59259-145-9
eBook Packages: Springer Protocols